Literature DB >> 24142330

Improvement of sleep disturbance and insomnia following parathyroidectomy for primary hyperparathyroidism.

Sara E Murray1, Priya R Pathak, Sarah C Schaefer, Herbert Chen, Rebecca S Sippel.   

Abstract

BACKGROUND: The aim of the present study was to investigate the incidence of sleep disturbance and insomnia in patients with primary hyperparathyroidism (PHPT), and to evaluate the effect of parathyroidectomy.
METHODS: A questionnaire was prospectively administered to adult patients with PHPT who underwent curative parathyroidectomy over an 11-month period. The questionnaire, administered preoperatively and 6 months postoperatively, included the Insomnia Severity Index (ISI) and eight additional questions regarding sleep pattern. Total ISI scores range from 0 to 28, with >7 signifying sleep difficulties and scores >14 indicating clinical insomnia.
RESULTS: Of 197 eligible patients undergoing parathyroidectomy for PHPT, 115 (58.3 %) completed the preoperative and postoperative questionnaires. The mean age was 60.0 ± 1.2 years and 80.0 % were women. Preoperatively, 72 patients (62.6 %) had sleep difficulties, and 29 patients (25.2 %) met the criteria for clinical insomnia. Clinicopathologic variables were not predictive of clinical insomnia. There was a significant reduction in mean ISI score after parathyroidectomy (10.3 ± 0.6 vs 6.2 ± 0.5, p < 0.0001). Postoperatively, 79 patients (68.7 %) had an improved ISI score. Of the 29 patients with preoperative clinical insomnia, 21 (72.4 %) had resolution after parathyroidectomy. Preoperative insomnia patients had an increase in total hours slept after parathyroidectomy (5.4 ± 0.3 vs 6.1 ± 0.3 h, p = 0.02), whereas both insomnia patients and non-insomnia patients had a decrease in the number of awakenings (3.7 ± 0.4 vs 1.9 ± 0.2 times, p = 0.0001).
CONCLUSIONS: Sleep disturbances and insomnia are common in patients with PHPT, and the majority of patients will improve after curative parathyroidectomy.

Entities:  

Mesh:

Year:  2014        PMID: 24142330      PMCID: PMC3945278          DOI: 10.1007/s00268-013-2285-1

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  36 in total

1.  Validation of the Insomnia Severity Index as an outcome measure for insomnia research.

Authors:  C H. Bastien; A Vallières; C M. Morin
Journal:  Sleep Med       Date:  2001-07       Impact factor: 3.492

2.  Prospective surgical outcome study of relief of symptoms following surgery in patients with primary hyperparathyroidism.

Authors:  J L Pasieka; L L Parsons
Journal:  World J Surg       Date:  1998-06       Impact factor: 3.352

3.  Detecting insomnia: comparison of four self-report measures of sleep in a young adult population.

Authors:  S Smith; J Trinder
Journal:  J Sleep Res       Date:  2001-09       Impact factor: 3.981

4.  Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: patient description and effects on the SF-36 health survey.

Authors:  G B Talpos; H G Bone; M Kleerekoper; E R Phillips; M Alam; M Honasoge; G W Divine; D S Rao
Journal:  Surgery       Date:  2000-12       Impact factor: 3.982

5.  Patient-based surgical outcome tool demonstrating alleviation of symptoms following parathyroidectomy in patients with primary hyperparathyroidism.

Authors:  Janice L Pasieka; Louise L Parsons; Michael J Demeure; Stuart Wilson; Peter Malycha; Jean Jones; Beth Krzywda
Journal:  World J Surg       Date:  2002-05-21       Impact factor: 3.352

6.  Psychiatric morbidity in primary hyperparathyroidism.

Authors:  S J McAllion; C R Paterson
Journal:  Postgrad Med J       Date:  1989-09       Impact factor: 2.401

7.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

8.  Surgical correction of primary hyperparathyroidism improves quality of life.

Authors:  R E Burney; K R Jones; M Peterson; B Christy; N W Thompson
Journal:  Surgery       Date:  1998-12       Impact factor: 3.982

9.  Neuropsychologic deficits associated with primary hyperparathyroidism.

Authors:  P J Numann; A J Torppa; A E Blumetti
Journal:  Surgery       Date:  1984-12       Impact factor: 3.982

10.  Interleukin-6 production and secretion by human parathyroids.

Authors:  S A Safley; F Villinger; E H Jackson; C Tucker-Burden; C Cohen; C J Weber
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

View more
  6 in total

1.  Elevated parathyroid hormone after parathyroidectomy delays symptom improvement.

Authors:  Priya R Pathak; Sara E Holden; Sarah C Schaefer; Glen Leverson; Herbert Chen; Rebecca S Sippel
Journal:  J Surg Res       Date:  2014-03-02       Impact factor: 2.192

2.  Is intraoperative parathyroid hormone testing in patients with renal insufficiency undergoing parathyroidectomy for primary hyperparathyroidism accurate?

Authors:  Jonathan A Sohn; Sarah C Oltmann; David F Schneider; Rebecca S Sippel; Herbert Chen; Dawn M Elfenbein
Journal:  Am J Surg       Date:  2014-12-17       Impact factor: 2.565

3.  [Validation and testing of the Russian version of PHPQoL questionnaire for quality of life assessment in patients with primary hyperparathyroidism (PHPT)].

Authors:  I N Gladkova; V F Rusakov; R A Chernikov; Yu V Karelina; T P Nikitina; S M Efremov; T I Ionova
Journal:  Probl Endokrinol (Mosk)       Date:  2021-01-19

4.  The impact of patient age on practice patterns and outcomes for primary hyperparathyroidism.

Authors:  Whitney Sutton; Joseph K Canner; Jessica B Shank; Abbey L Fingeret; Shkala Karzai; Dorry L Segev; Jason D Prescott; Aarti Mathur
Journal:  Am J Surg       Date:  2022-03-19       Impact factor: 3.125

Review 5.  Primary Hyperparathyroidism.

Authors:  Leonardo Bandeira; John Bilezikian
Journal:  F1000Res       Date:  2016-01-04

Review 6.  Should Symptoms Be Considered an Indication for Parathyroidectomy in Primary Hyperparathyroidism?

Authors:  Alexandria D McDow; Rebecca S Sippel
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2018-06-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.